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Abstract 
Background & Aim: Anemia is commonly associated with acute and chronic 
inflammation, but the mechanisms of their interaction are not clear. We investigated 
whether microRNA 122 (MIR122), which is generated in the liver and is secreted into 
the blood, is involved in the development of anemia associated with inflammation.  
 
Methods: We characterized the primary transcript of the human liver-specific 
MIR122 using northern blot, quantitative real-time PCR, and 3' and 5' RACE 
analyses. We studied regulation of MIR122 in human hepatocellular carcinoma 
(HCC) cell lines (Huh7 and HepG2) as well as in C57BL/6 and mice with disruption 
of the tumor necrosis factor gene (Tnf). Liver tissues were collected and analyzed by 
bioluminescence imaging or immunofluorescence.  Inflammation in mice was induced 
by lipopolysaccharide (LPS) or by cerulein injections. Mice were given 4 successive 
injections of LPS, leading to inflammation-induced anemia. Steatohepatitis was 
induced with a choline-deficient high-fat diet. Hemolytic anemia was stimulated by 
phenylhydrazine injection. MIR122 was inhibited in mice by tail-vein injection of 
antogomiR-122 (an oligonucleotide antagonist of MIR122). MicroRNA and mRNA 
levels were determined by quantitative real time PCR.   
 
Results: The primary transcript of MIR122 spanned 5 kb, comprising 3 exons; the 
third encodes MIR122. Within the MIR122 promoter region we identified a nuclear 
factor-κB (NF-κB) binding site and demonstrated that RELA, as well as activators of 
NF-κB (TNF and LPS), increased promoter activity of MIR122. Administration of 
LPS to mice induced secretion of MIR122 into blood, which required TNF. Secreted 
MIR122 reached the kidney and reduced expression of erythropoietin (Epo), which 
we identified as a MIR122 target gene. Injection of mice with antagomiR-122 
increased blood levels of EPO, reticulocytes, and hemoglobin. We found an inverse 
relationship between blood levels of MIR122 and EPO in mice with acute pancreatitis 
or steatohepatitis, and also in patients with acute inflammation.  
 
Conclusion: In mice, we found that LPS-induced inflammation increases blood levels 
of MIR122, which reduces expression of Epo in the kidney; this is a mechanism of 
inflammation-induced anemia. Strategies to block MIR122 in patients with 
inflammation could reduce the development or progression of anemia.  
 
KEY WORDS: microbiome, NASH, mouse model, red blood cells 
 
Introduction 
MicroRNA-122 (miR-122) is a highly abundant liver-specific microRNA whose 
sequence is conserved in vertebrates1. MiR-122 plays a role in cholesterol and fatty-
acid metabolism2, in apoptosis3, hepatocellular carcinoma (HCC) growth4, 5, and in 
hepatitis C virus (HCV) propagation6. MiR-122 is secreted into the blood stream and 
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changes in its blood level were suggested as a predictive marker for viral-, alcohol- 
and chemical-induced liver injury7, 8. 
Expression of miR-122 is regulated by a number of transcription factors including 
hepatocyte nuclear factors HNF1α, HNF3β, HNF4α and by C/EBPα9-11 
(CAAT/enhancer-binding protein). MiR-122 expression was also shown to be 
epigenetically regulated by the PPARγ/RXRa complex12. Additionally, miR-122 is 
regulated by Rev-ErbA alpha suggesting that miR-122 is a circadian metabolic 
regulator13. 
Lately, NF-κB was found to regulate the expression of various microRNA genes14-16. 
NF-κB is a stimulatory transcription factor, controlling immunity and inflammation 
and important cellular processes, ranging from cell growth and differentiation to 
apoptosis, cancer and in particular HCC, as we have shown17. NF-κB consists of a 
family of hetero- or homo-dimers frequently including one subunit of P65 (RelA) and 
a second subunit such as P50, c-Rel or RelB18. Among the various stimuli responsible 
for NF-κB activation are the pro-inflammatory cytokine TNFα and bacterial 
lipopolysaccharide (LPS)19. LPS is a major membrane component of gram negative 
bacteria, constituting a significant fraction of the gut-microbiome bacterial 
population. When the lining of the intestine becomes leaky, LPS can get into the 
bloodstream and reach the liver through the portal system.  Consequently, LPS 
triggers an acute-phase inflammatory response and induces anemia20 by affecting the 
level of erythropoietin (EPO). EPO is essential for the viability and proliferation of 
erythrocytic progenitors and in adults, it is predominantly synthesized in the 
kidneys21. 
We characterized the structure of the human miR-122 primary transcript and its 
promoter, and we demonstrate that the miR-122 promoter is enhanced by NF-κB , 
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TNFα and LPS. We also show that TNFα and LPS enhance the secretion of miR-122 
into the blood. We established that Epo is a target of miR-122, and upon reducing 
miR-122 blood levels, we could reverse anemia. Importantly, we found an inverse 
correlation between EPO and miR-122 levels in the blood of mice with acute and 
chronic inflammation and in blood of human patients with acute inflammation. This 
work shows that miR-122 acts like a hormone, linking the gut, liver and kidney in 
controlling EPO levels. Our observations are the first to show a direct link between a 
microRNA and inflammation-induced anemia and may constitute a basis for a novel 
therapeutic approach to reverse the anemic condition via reduction of miR-122 levels 
 
Materials and methods 
Animal Studies 
 Male and female C57BL/6 mice, 7-8 weeks old, were purchased from Harlan 
Laboratories (Jerusalem, Israel). Tnfα-deficient mice (TNFα KO) in a C57BL/6 
background were a gift from Dr. Moshe Sade-Feldman and Prof. Michal Baniyash 
(Hebrew University Jerusalem). All mice were kept in a pathogen-free facility, under 
a 12 h light/dark cycle. Research on mice was approved by the Hebrew University 
Institutional Animal Care and Ethics Committee. 
 
Cell Lines and Cell Culture 
HCC-derived human cell lines: Huh7, HepG2 and Hep3B, and human non-hepatic 
cell lines HEK293 - embryonic kidney cells, HeLa - epithelial cells from a cervical 
carcinoma, P10 - Foreskin fibroblasts and U2OS - osteosarcoma cell lines, were 
cultured in DMEM supplemented with 10% fetal calf serum (FCS), 1% 
penicillin/streptomycin. Exposing a cell culture to hypoxic conditions (5% CO2, and 
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less than 0.1% O2) was achieved using an anaerobic jar equipped with AnaeroPack 
(Mitsubishi Gas Chemical, Tokyo, Japan). 
 
Reagents 
LPS (E. coli 0111:B4, cat # L-2630) was purchased from Sigma-Aldrich Chemical 
Co., (St. Louis, MO). Recombinant human TNFα (210-TA) was obtained from R&D 
systems (Minneapolis, MN). SC-514 (50µM) was obtained from (Calbiochem).  
 
Additional information is available in the Supplementary Materials and Methods 
section.  
 
Results 
Characterization of the miR-122 primary transcript 
The miR-122 primary transcript, pri-miR-122, was identified in woodchuck liver 
tumors as a non-coding transcript named hcr and subsequently identified in mouse 
livers as a ~5 kb miR-122 precursor RNA22. We dissected pri-miR-122 from human 
liver RNA and found that miR-122 is generated from the third exon of pri-miR-122 
which spans 5012 bases and contains 3 exons that bear typical splicing signals at the 
exon-intron borders (Figure 1A and Supplementary Figures 1 and 2).  
 
Enhancement of miR-122 expression by NF-κB  
A number of transcription factors affect the expression of miR-122 (see 
introduction). We identified bioinformatically a putative NF-κB consensus sequence 
within the miR-122 promoter region at position -170 relative to the transcription start 
site (TSS). We generated a Luciferase reporter plasmid carrying the human miR-122 
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promoter from -900 to +270 bp relative to the TSS, (PmiR-122-900) (Supplementary 
Figure 3A) and measured its activity in various human liver-derived and non-liver cell 
lines. We observed high expression levels only in Huh7 cells and relatively low 
expression in non-hepatic cell lines (Supplementary Figure 4A). Dissecting the 
promoter region from the 5'-end revealed that full promoter activity was retained 
when the sequence extended to -250 bp upstream from the TSS (Supplementary 
Figure 4B). Importantly, we established that miR-122 is produced solely from the 
transcript generated from this promoter, using plasmids carrying the full length miR-
122 genomic region, with or without this upstream promoter, and containing 
mutations in the pre-miR-122 region to distinguish it from endogenous miR-122 
(Supplementary Figure 5). 
To study the effect of NF-κB  on miR-122 promoter activity, we co-transfected 
Huh7 cells with the PmiR-122-900 or -250 reporter plasmids, together with a plasmid 
expressing the human RelA (P65) gene. As a positive control, we used an NF-κB  
reporter plasmid. P65 enhanced significantly the miR-122 promoter of both lengths 
(Figure 1B).  
We next tested the effect of TNFα, a known NF-κB activator, on miR-122 
promoter activity. Huh7 cells were transfected with PmiR-122-900 and 24 hours later, 
human TNFα was added for 2, 6 and 24 hours, with, or without the NF-κB inhibitor 
SC-514 23. Figure 1C shows that TNFα significantly stimulated the miR-122 
promoter, and this stimulation was greatly reduced by SC-514. Similarly, TNFα 
enhancement was inhibited by another NF-κB inhibitor, IKB∆N, a dominant-negative 
mutant of IKB 24 indicating that TNFα activation is NF-κB-dependent 
(Supplementary Figure 6A). TNFα did not affect the activity of the human AAT or the 
EF1α promoters (Supplementary Figure 6B). Additionally, TNFα promoter 
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enhancement was followed by an increase in both, pri-miR-122 and mature miR-122 
levels (Supplementary Figure 7).  
To verify that NF-κB activation involves binding to the miR-122 promoter, we 
mutated the predicted NF-κB site (Figure 1D). These mutations caused significant 
reduction in miR-122 promoter activity and completely abolished enhancement by 
P65 and TNFα in Huh7 cells (Figure 1E and F). Furthermore, direct proof for NF-κB 
binding to the miR-122 promoter region was obtained by chromatin 
immunoprecipitation ChIP assay performed on Huh7 cells treated for 2 and 16 hours 
with TNFα (Supplementary Figure 14). 
The NF-κB binding coincides with a C/EBPα consensus (Figure 1D), previously 
shown to enhance miR-122 promoter expression11. However, in our experiments, 
C/EBPα significantly repressed the activity of both, the wild type and mutated PmiR-
122 promoter (Supplementary Figure 8). As a positive control for C/EBPα we used 
the IL-8 reporter plasmid which is also activated by NF-κB 25.  
We next tested the effect of LPS, a known NF-κB activator, on miR-122 promoter 
activity in vivo. C57Bl/6 mice were injected with plasmid PmiR-122-900 and imaged 
for luciferase signals one day later, and then injected i.p. with either LPS or saline, 
and imaged again after  3 hours, and at days 1, 2, 5, 6 and 7 post-injection. As seen in 
Figure 2A, LPS activated significantly the human miR-122 promoter. A second LPS 
injection at day 5 caused considerable re-activation. Furthermore, the plasmid 
carrying the mutant miR-122 promoter, when injected into mice, exhibited low 
activity and was only mildly induced by LPS (Figure 2B). We demonstrate that tail 
vein-injected reporter plasmid enters hepatocytes, using a PmiR-122 GFP reporter 
plasmid followed by immunostaining of liver sections for GFP (Supplementary Figure 
13). MiR-122 promoter activity exhibited enhancement by LPS.  
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Analysis of endogenous pre-miR-122 and mature miR-122 in mice livers following 
LPS administration revealed enhancement of pre-miR-122 at 5 and 24 hours, whereas 
mature miR-122 increased significantly after 5 hours but this increase was not 
retained at 24 hours post LPS injection (Figure 2C and D).  
 
TNFα and LPS enhance secretion of miR-122 
MicroRNAs, including miR-122, were found to circulate in the bloodstream 26, 27. 
In addition, secreted microRNAs can silence their target genes in remote tissues, 
thereby playing a role in cell-to-cell communication28, 29.  
To test whether TNFα also affects miR-122 secretion, we measured microRNA 
levels in conditioned medium of cultured Huh7 cells treated with TNFα for 24 hours. 
Figure 3A demonstrates that the growth medium of non-treated Huh7 contains a 
certain level of miR-122 as well as the control miR-16 and miR-18, previously shown 
to be secreted30, 31. Addition of TNFα greatly enhanced miR-122 secretion, without 
affecting the level of secreted miR-16 or miR-18. To eliminate the possibility that 
increased miR-122 secretion was due to cell death, we performed a cell proliferation 
assay, which demonstrated that no change in living cell numbers occurred in the 
TNFα-treated culture (Figure 3B). 
To test whether LPS also induces secretion of miR-122, we injected mice i.p. with 
LPS and quantified miR-122 levels in plasma samples drawn before, and at 4 and 24 
hours after injection. Following LPS administration, miR-122 serum levels increased 
already after 4 hours (4 fold) and by 24 hours, a dramatic increase was observed 
(Figure 3C). This increased miR-122 secretion 24 hours after LPS administration, 
may explain the observed decrease in mature liver miR-122 levels between 5 and 24 
hours after LPS treatment (Figure 2D).  
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Since LPS is known to induce TNFα production32, we injected LPS into TNFα 
knockout (KO) mice. In these TNFα KO mice, LPS did not induce the secretion of 
miR-122 to the plasma (Figure 3D), indicating that indeed, induction of miR-122 
secretion by LPS is TNFα-dependent. To rule out the possibility that damaged 
hepatocytes contributed to increased miR-122 plasma levels, we measured plasma 
ALT and AST enzyme levels (biomarkers of liver injury) and found no change 
between LPS-treated and control mice (not shown). 
We next investigated whether secreted miR-122 is taken up by remote tissues 24 
hours following LPS administration. The level of miR-122 was extremely low in all 
tissues compared to the liver, and were not significantly affected by LPS except for a 
significant increase observed in the kidney (Figure 3E).  
 
Erythropoietin is a target of miR-122 
Our finding that LPS causes an increase in miR-122 plasma levels, prompted us to 
search for miR-122 target genes known to be affected by inflammation.  
Bioinformatic search revealed that erythropoietin (Epo) is a predicted miR-122 target, 
carrying putative miR-122 binding sites in its 3’-UTR region; three sites in the human 
and two in the mouse Epo (Supplementary Figure 9). We cloned the 3’-UTR regions 
carrying two miR-122 target sites of the mouse and human Epo gene (sites1+2), 
downstream of the luciferase gene in the pmirGLO plasmid, and used them to 
transfect HEK293 cells together with miR-122 or scrambled miR control. As a 
positive control for miR-122 activity, we used a construct carrying the 3’-UTR of 
AldoA, a verified miR-122 target2.  A plasmid carrying the 3’-UTR of the DNMT1 
gene served as a negative control.  Both, the human and mouse Epo-3’UTR constructs 
demonstrated significant reduction in luciferase activity in the presence of miR-122, 
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similar to the AldoA reporter (Figure 4A). To further confirm that Epo is a true miR-
122 target, we mutated the miR-122 site2 target in the human EPO 3’-UTR construct 
(the evolutionary conserved site) (Supplementary Figure 9D) and that diminished 
significantly the inhibitory effect of miR-122 on Luciferase expression (Figure 4B).  
To demonstrate that miR-122 affects endogenous Epo mRNA levels, we 
transfected human HCC-derived cells, Hep3B, with miR-122 or miR-control and 24 
hours later, exposed the cells to hypoxic condition, in order to increase endogenous 
EPO expression21. Six hours after exposure to hypoxic conditions, Epo mRNA levels 
were greatly induced and this induction was dramatically suppressed by miR-122, but 
was unaffected by the control microRNA, implying that Epo is a true miR-122 target 
gene (Figure 4C). 
 
The effect of miR-122 on EPO expression levels in mice 
To study the in vivo effect of miR-122 on EPO levels, we injected miR-122 into mice 
treated with phenylhydrazine (PHZ) which is known to cause lysis of RBCs, resulting 
in hemolytic anemia33 and increased EPO levels. PHZ was injected i.p. into mice on 
two consecutive days and 4 days later, the mice were injected i.v. with miR-122, miR-
scrambled (negative control) or siEPO (positive control). Two days after miR-122 
injection, miR-122 plasma levels, as expected, were high (Supplementary Figure 10A) 
whereas EPO plasma levels were significantly reduced, similar to the reduction 
observed with siEPO, as compared to miR-control (Figure 4D).  
In a reciprocal experiment, we reduced miR-122 levels by administration of 
antagomiR-122, (a cholesterol-modified RNA oligonucleotide2 ) by hydrodynamic 
tail vein injection, 48 hours prior to treatment with PHZ (see Supplementary Figure 
10B). Inhibition of miR-122 caused a significant increase in EPO plasma levels which 
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was maintained for 12 days after PHZ injection (Figure 4E). An increase in 
reticulocyte numbers was apparent already at day 7, whereas the effect on hemoglobin 
levels was observed only on day 12 post- PHZ treatment. This is in line with previous 
observations that recovery of hemoglobin occurs more than one week following PHZ 
treatment34. These data substantiate the involvement of miR-122 in the regulation of 
EPO plasma levels following acute PHZ-induced anemia.  
 
An inverse relationship between EPO and miR-122 in mice models of 
acute inflammation 
We wanted to assess the relationship between miR-122 and EPO levels in 
mice models of acute inflammation. A model of acute pancreatitis was generated by 
repeated i.p. injections of cerulein (a cholecystokinin analogue) into mice35. This 
treatment was previously shown to rapidly activate NF-κB36. Following cerulein 
injections, we observed a significant increase in mature miR-122 levels in the plasma, 
concomitant with reduced levels of plasma EPO levels (Figure 5A). A similar inverse 
miR-122/EPO relationship was also observed in the kidney (Figure 5B).  
We next studied the correlation between miR-122 and EPO levels in acute 
inflammation induced by LPS. We injected mice with LPS and five hours later, we 
measured the levels of EPO, miR-122 and TNFα in the different tissues. As expected, 
mRNA levels of TNFα in the liver and in the kidney were greatly induced 
(Supplementary Figure 11A and B). LPS injection, which induces miR-122 secretion 
from the liver (see Figure 3C), resulted in a significant increase in the level of mature 
miR-122 in the kidney. In parallel, LPS induced a dramatic reduction in both, EPO 
mRNA levels in the kidney and EPO protein level in the blood (Figure 5C). In 
addition to EPO mRNA, at 5 and 24 hours after LPS injection, we observed in the 
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kidney, a reduction of two other miR-122 validated targets, AldoA and AGPAT137 
(Figure 5D and Supplementary Figure 11C). The effect of miR-122 on its targets in 
the kidney was stronger at 24 hours compared to 5 hours after LPS treatment.  
To further demonstrate that miR-122 is involved in the reduction of EPO 
levels following LPS injection, we repressed miR-122 liver levels by hydrodynamic 
tail vein injection of antagomiR-122, prior to LPS injection. This injection method 
ensures that antagomiRs reach the liver without affecting other organs38. Upon 
administration of antagomiR-122, plasma EPO protein level was significantly higher 
than that of mice injected with the control antagomiR-124. Furthermore, the kidney 
mRNA levels of EPO and the miR-122 targets AldoA and AGPAT1, were also 
significantly higher in antago-miR-122 treated mice (Figure 5E). This suggests that 
following LPS treatment, liver-generated circulating miR-122, reaches the kidney and 
regulates the expression level of its target genes, including EPO.  
Further support for this hypothesis comes from our experiments in which the 
major source for TNFα production namely, macrophages and Kupffer cells, were 
depleted by liposome-delivered Clodronate39. As shown above (Figure 3D), LPS 
induction of miR-122 expression is TNFα-dependent. Figure 6A, depicting F4/80 
immunostaining for macrophages, revealed that in mice i.p. injected with clodronate 
two days prior to LPS treatment, liver macrophages were abbolished entirely but 
kidney macrophages were not affected. Accordingly, TNFα and IL-6 levels in the 
liver were greatly suppressed but not in the kidney where they were even slightly 
enhanced (Figure 6B). However, miR-122 levels both, in the blood and in the kidney, 
were significantly reduced and EPO blood levels had increased (Figure 6C,D). 
Concomitantly, the miR-122 target genes, AldoA and CAT-1 had increased (Figure 
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6E). These data suggest that the major source of miR-122 in the kidney stems from 
circulating blood miR-122.  
 
 
 
The development of anemia following inflammation is mediated by miR-
122  
In a mouse model of chronic inflammation, we analyzed the plasma of twelve 
months old CD-HFD mice bearing features resembling human nonalcoholic 
steatohepatitis (NASH), induced by long-term feeding of a Choline-Deficient-High-
Fat Diet40 (CD-HFD). Comparable to the acute inflammation induced by LPS and by 
cerulein, miR-122 levels were dramatically elevated in the plasma of these CD-HFD 
mice, whereas the level of EPO protein was significantly lower. Importantly, the 
hemoglobin level in these mice was statistically lower as compared to control mice 
(Figure 7A).  
To demonstrate the development of anemia following LPS-induced 
inflammation, we treated mice with four successive injections of LPS at days 0, 2, 4 
and 7 and sacrificed the mice at days 1, 6, 8 and 11. As seen in Figure 7B, hemoglobin 
levels were reduced significantly already at day 6 and declined further up to day 8 and 
gradually increased thereafter. To determine the involvement of miR-122 in the 
development of anemia, we inhibited miR-122 by injecting mice with antagomiR-122. 
As seen in Figure 7D, at five hours after LPS injection, antagomiR-122 treatment 
resulted in a decrease in miR-122 in the blood and in the kidney, concomitant with a 
significant increase in EPO plasma level. At day 7, antagomiR-122 exhibited no 
significant effect on EPO and miR-122 kidney levels, but still repressed miR-122 in 
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the blood, although to a lesser extent. Most importantly, antagomiR-122 treatment 
resulted in a significant increase in mice hemoglobin levels at day 7, signifying the 
involvement of miR-122 in the development of anemia following LPS treatment. 
Notably, histological analysis revealed no extramedullary hematopoiesis (not shown) 
and furthermore, no apparent change was observed in spleen size or weight in these 
treated mice (Supplementary Figure 12).  
 
An inverse correlation between EPO and miR-122 in human patients with 
acute inflammation 
To learn whether a similar inverse correlation between EPO and miR-122 is 
reproduced in humans with inflammation, we conducted a prospective investigation in 
patients with an acute bacterial infection (clinical diagnosis shown in Supplementary 
Table 4). Plasma samples were collected upon admission to the hospital and a few 
days later during hospitalization, and were analyzed for miR-122 and EPO protein 
levels. We observed that in 12 out of the17 patients tested, miR-122 levels continued 
to rise whereas EPO levels decreased (Supplementary Table 4).  These changes that 
occurred in the plasma levels of miR-122 and EPO during the acute infection state, 
exhibited a statistically significant inverse correlation, corresponding to the results 
observed in the inflammatory mouse models (Figure 7E).   
 
Discussion 
MiR-122 exhibits pleiotropic functions in mammals. In this study we present 
evidence that miR-122 plays a role in inflammation-induced anemia as well. We 
characterized the structure of the miR-122 primary transcript and dissected the 
promoter region. Our analysis revealed that miR-122 is derived from the third and last 
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exon of a 5kb non-coding RNA, which is similar in length to the mouse pri-miR-122. 
It is still unknown whether the long, non-coding pri-miR-122 RNA has a function 
other than serving as a miR-122 precursor. We show that the pro-inflammatory 
mediators, LPS and TNFα, enhance miR-122 promoter activity through the activation 
of NF-κB and moreover, they enhance the secretion of miR-122 from the liver into 
the bloodstream.  
We have unfolded steps linking miR-122 to inflammation-induced anemia. We 
demonstrate that Epo is a miR-122 target gene. We next show that in mice models of 
acute inflammation induced by LPS and cerulein, as well as in chronic inflammation 
in CD-HFD mice, there is induction of miR-122 secretion to the blood, concurrent 
with a significant decrease in EPO protein levels. Thus, an inverse correlation 
between EPO protein and miR-122 levels occurs in the blood upon inflammation. In 
addition, we observed that secreted miR-122 reached the kidney, the major site of 
EPO synthesis in adults, where it caused a reduction in EPO mRNA levels, as well as 
two other known mir-122 target genes, AldoA and AGPAT1. Furthermore, in mice 
injected repeatedly with LPS and in CD-HFD mice, the inverse miR-122/EPO 
relationship was associated with anemia.  
Interestingly, our data suggest that the hepatic iron-regulatory hormone hepcidin 
(which is induced in response to inflammation, including LPS, and is thought to be 
responsible for the development of anemia of inflammation in various disease states 
but not in all) is not directly associated with the events leading to the inverse miR-
122/EPO relationship. Importantly, miR-122 was previously shown to be a negative 
regulator of hepcidin46. In our CD-HFD mice, where miR-122 is induced, hepcidin 
liver mRNA levels were dramatically reduced. Upon Cerulein or LPS treatment, 
hepcidin mRNA levels increased at 6 hours but in the case of LPS, hepcidin mRNA 
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levels returned to the control level thereafter. As expected, inhibition of miR-122 by 
antagomir-122, followed by LPS injection, resulted in significant increased levels of 
hepcidin (Supplementary Figure 15). 
Support for our proposition that the source of kidney miR-122 is from circulating 
blood miR-122 which originates in the liver, comes from our experiment with 
macrophage depletion in the liver by Clodronate. Contrary to the liver, macrophages 
and TNFα levels in the kidney were not affected and yet, miR-122 levels were 
significantly reduced in the kidney. In accordance, we could not detect the presence of 
pre-miR-122 precursor in the kidney as opposed to its high induction by LPS in the 
liver (Figure 2C). 
Importantly, we found an inverse miR-122/EPO correlation also in blood of human 
patients afflicted with anemia associated with acute inflammation. In the majority of 
the patients tested at the acute inflammation stage and a few days later, miR-122 
blood levels continued to rise whereas EPO levels were decreased. 
When induction of inflammation in mice was preceded by inhibition of miR-122 
by antagomiR-122 injection (known to inhibit liver miR-122), EPO plasma levels, 
reticulocyte number and hemoglobin levels were all restored. Based on our results, we 
propose a model (Figure 7F) in which inflammation that induces TNFα, activates NF-
κB which in turn, induces expression and secretion of mir-122 from the liver into the 
blood. Circulating miR-122 then reaches the kidney where it represses EPO, 
eventually leading to the development of anemia.  
Recombinant EPO (rhEPO) is frequently prescribed, at high amounts, to treat 
anemia in patients with chronic kidney disease and cancer. However, rhEPO could 
potentially accelerate tumor growth and jeopardize patient survival41 and may also 
facilitate cardiovascular events. EPO and its receptor, EPOR, are expressed in many 
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cancers including hepatocellular carcinoma42, 43. EPO may also stimulate epithelial-
mesenchymal transition (EMT) associated with cancer progression44. These risks 
associated with rhEPO treatment should be an incentive for developing alternative 
therapies. 
Targeting of EPO by miR-122 is clinically significant, since it results in a 
concomitant reduction in red blood cell precursors and hemoglobin levels. Thus, by 
reducing miR-122 serum levels, endogenous EPO levels may increase. Inhibition of 
miR-122 can be achieved with antagomiR-122, shown in animals to have a long-term 
effect45. Therefore, antagomiR-122 could potentially offer a novel clinical and cost-
effective therapy to reverse anemic conditions in patients and thus, substitute for the 
usage of rhEPO.  
Our findings add additional support to the currently growing understanding that 
microRNAs could act as “nucleic acid hormones”. We describe the inter-organ cross-
talk between the gut microbiome, the source of LPS, which induces TNFα in the liver 
to enhance miR-122, which is secreted to the blood and reaches the kidney to target 
EPO that consequently reduces bone marrow erythropoiesis.  
In summary, our findings establish the importance of miR-122 in linking 
inflammatory signals to the onset of anemia thus offering a new and additional insight 
into the underlying mechanism of inflammation-induced anemia.  
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Figure Legends 
Figure 1. Enhancement of miR-122 by NF-κB and TNFα.  (A) A schematic presentation of pri-
miR-122 with the sizes of the 3 exons and the introns and its coordinates in the USCS 
2013/hg38 assembly. (B) The effect of RelA on miR-122 promoter activity. Huh7 cells were co-
transfected with miR-122 promoter reporter plasmids PmiR-122-900 or PmiR-122-250, or an 
NF-κB reporter plasmid (NF-κB), together with a plasmid expressing the P65 gene (RelA). 
Luciferase (Luc) activity was measured 48hrs after transfection.  (C) Enhancement of miR-122 
promoter by TNFα is NF-κB dependent. Huh7 cells transfected with PmiR-122-250 were treated 
24hrs later with TNFα (5ng/ml). The SC-514 NF-κB inhibitor (50 µM) was added 45 minutes 
before the addition of TNFα.  Luciferase activity was measured at the indicated times after 
TNFα addition. (D) The sequence of the putative NF-κB-C/EBPα site in the miR-122 promoter 
and the 3 mutations that were introduced therein. (E and F) Relative Luciferase activity in Huh7 
cells transfected with the wild type (wt) or mutated (mut) PmiR-122 plasmids, and either co-
transfected with the P65-expressing plasmid (E), or treated one day after transfection with 
TNFα for 24hrs (F). Luciferase activity was measured 48hrs after transfection and normalized to 
Renilla Luciferase activity expressed from a co-transfected pRL plasmid. Error bars = SD. *P< 
0.05; **P< 0.01. 
 
 
 Figure 2. LPS enhances miR-122 expression. (A) Induction of the miR-122 promoter by LPS. 
Mice were i.v. hydrodynamically injected with PmiR-122-900 and one day later (day 0) imaged 
for luciferase activity. LPS (1mg/kg) was then injected i.p. and the mice were imaged 3hrs later 
and at the following 1, 2, 5, 6 and 7 days. A second LPS injection was administered at day 5. 
Control mice were injected with saline. Shown are images of luciferase activity in representative 
mice and the quantification of liver luciferase activity from the imaging data, expressed as the 
ratio between LPS-injected and control, saline-injected, mice (n=7). (B) LPS activates the miR-
122 promoter in an NF-κB-dependent manner. Quantification of imaging data of mice 
hydrodynamically injected with reporter plasmids carrying the wt or mutant PmiR-122-900 
promoter, and 1 day later, injected i.p. with LPS and imaged 24hrs thereafter (n=3). (C,D) LPS 
induces Pre-miR-122 (C) and mature miR-122 (D) levels determined by qRT-PCR on liver 
RNA extracted from mice 5 and 24hrs after injection of LPS or saline (Control) (n=5). Mature 
miR-122 was normalized to RNU-6, pri-miR-122 and pre-miR-122 levels were normalized to 
HPRT. Error bars = SD. *P< 0.05; **P< 0.01. 
 
Figure 3. TNFα and LPS induce secretion of miR-122. (A) qRT-PCR analysis of miR-122 
performed on RNA extracted from the culture medium of Huh7 cells treated with TNFα for 
24hrs. (B) Cell proliferation assay performed on the culture medium of TNFα-treated Huh7 cells 
using the CellTiter96 kit. Doxorubicin (2 µg/ml) (DOX) was used as a positive control for cell 
death. (C-E) qRT-PCR analysis of miR-122 performed on RNA extracted from: (C) plasma 
taken from mice treated with LPS for 4 and 24hrs; (D) plasma of wild type C57BL/6 (WT) or 
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TNFα KO mice analyzed 24hrs after LPS or saline (Control) injection; (E) RNA from various 
tissues extracted 24hrs after LPS injection (n=4). Tissue miR-122 level was normalized to RNU-
6; plasma and medium miR-122 was normalized to spiked-in cel-miR-39. Error bars = SD.  *P< 
0.05; **P<0.01. 
 
Figure 4. Erythropoietin (EPO) is a miR-122 target gene. (A) HEK293 cells were co-transfected 
with the mouse EPO 3’-UTR (mEPO) or human (hEPO) reporter plasmids, together with 50nM 
miR-122 (miR-122) or scrambled miR (miR-con). Reporter plasmids carrying the AldoA or the 
DNMT1 3'-UTR served as positive and negative controls, respectively. (B) HEK293 cells were 
transfected with reporter plasmids carrying the WT or mutated (Mut) human EPO 3'-UTR 
together with miR-122 or miR-con. Luciferase assays were performed 48 hours after 
transfection (normalized to Renilla Luciferase activity). (C) Hep3B cells were transfected with 
miR-122 or with scrambled miR and 24hrs after transfection, transferred to hypoxic conditions 
for 6hrs and RNA was then extracted and analyzed for EPO mRNA levels by qRT-PCR. (D-E) 
The effect of miR-122 on hemoglobin, reticulocytes, and EPO blood levels in mice treated with 
Phenylhydrazine (PHZ). (D) EPO plasma levels in PHZ-treated mice. Mice injected i.p. on two 
successive days with PHZ (30 mg/kg) or with saline (NT). After 4 days, mice were injected i.v. 
with 0.1mg/mouse of miR-scrambled (miR-con), miR-122 or siEPO. Two days after miR 
injection, plasma EPO levels were measured using the Quantikine ELISA kit. (E) Mice were 
hydrodynamically injected with antagomiR-122 or control antagomiR-124 two days before 
treatment with PHZ. At the indicated days after PHZ treatment, blood was taken for 
measurements of EPO protein levels, % reticulocytes and hemoglobin (HB) levels (n=5). Error 
bars = SD. *P<0.05; **P<0.01. 
 
Fig. 5. Inverse correlation between miR-122 and EPO levels in mice models of acute 
inflammation. (A,B) Cerulein model. Mice were induced for acute pancreatitis by cerulein 
treatment (Cerul) involving 6 successive i.p. hourly injections (50 µg/kg) and were sacrificed 1 
hour after the last injection for measurement of plasma miR-122 and EPO protein levels (A) and 
for kidney miR-122 and EPO mRNA levels (B) (n=6). Control mice (Con) were injected with 
saline. (C) LPS model. Wild type C57BL/6 mice were injected i.p. with LPS (1 mg/kg) or saline 
(Control) and 5 hours later, RNA was extracted from the kidneys for qRT-PCR analysis of 
mature miR-122 and EPO mRNA levels and blood was taken for measurement of EPO protein 
level (n=4). (D) qRT-PCR analysis of kidney mRNA levels of EPO and the miR-122 validated 
targets AldoA and AGPAT1 measured 24hrs after LPS injection. RPL4 served as a negative 
control gene. (E) The effect of miR-122 inhibition by antagomiR-122. C57BL/6 mice were tail-
vein injected with antagomiR-122 (Ant-122) or control antagomiR-124 (Ant-124) (5µg/mouse) 
and 24hrs later, injected i.p. with LPS. 24hrs after LPS injection blood was taken for EPO 
protein measurement and RNA extracted from the kidneys for qRT-PCR analysis of the mRNA 
levels of EPO, AldoA and AGPAT1. Error bars = SD.  *P< 0.05; **P<0.01; ***P< 0.001. 
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Fig. 6. The effect of liver macrophage depletion on miR-122 plasma and kidney levels. Analysis 
of liver and kidney tissues taken 5hrs after LPS treatment from mice injected, 2 days prior to 
LPS-treatment, with Clodronate  (LPS Clodronate) or PBS (LPS Control) (n=4). (A) F4/80 
immunostaining of liver and kidney macrophages. (B) qRT-PCR analysis of TNFα and IL-6 
mRNAs in the liver and kidney. (C) qRT-PCR analysis of plasma and kidney miR levels. miR-
16 and miR-18 served as negative controls. (D) EPO protein levels in the plasma. (E) qRT-PCR 
of the miR-122 targets AldoA and CAT-1 in kidney. Error bars = SD.  *P< 0.05; **P<0.01; 
***P<0.001. 
 
Fig. 7. Inflammation-induced anemia is mediated by miR-122. (A) Chronic inflammation 
model. Blood samples taken from 12 months old CD-HFD C57BL/6 mice (HFD) or from mice 
fed a normal diet (Con), for measurements of plasma EPO protein and miR-122 levels, as well 
as blood hemoglobin level (n=5). (B) LPS model of inflammation-induced anemia. Mice were 
i.p. injected with LPS (0.5mg/kg) for four successive injections at days 0, 2, 4 and 7. Blood 
hemoglobin levels were determined at day 1, 6, 8 and 11 after the first LPS injection (n=6). 
(C,D) The effect of miR-122 inhibition by antagomiR on LPS-induced anemia. (C) 
Experimental design: mice were i.v. hydrodynamically injected with antagomiR-122 or 
antagomiR-Scr control (5µg/mouse) 3 days before and one day after the first LPS injection. Two 
additional LPS injections were administered at days 2 and 4. (D) Mice were sacrificed at 5hrs 
after the first LPS and at day 7 and analyzed for miR-122 and EPO plasma levels and for  miR-
122 kidney levels. Hemoglobin was measured at day 7. (E) Correlation analysis between 
changes in plasma EPO protein (∆ EPO) and miR-122 (∆ miR-122) levels measured during 
patient hospitalization for acute inflammation (Pearson correlation analysis r = -0.6415; 
P=0.0074) (see supplementary Table 4). Error bars = SD.  *P< 0.05; **P<0.01; ***P<0.001.  
(F) schematic presentation of our model of the involvement of miR-122 in inflammation-
induced anemia. 
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Supplementary Materials and Methods 
Plasmids  
The human miR-122 promoter fragments spanning the region from -900 or from -250 to 
+270 bp relative to the transcription start site (TSS) (plasmids PmiR-122-900 and PmiR-
122-250) were generated by PCR on human liver DNA using primers P20-P21 and P22-
P21 respectively and inserted into the PGL4 vector (Promega) upstream of the luciferase 
reporter gene (see Supplementary Figure 3 and Supplementary Table 3). Mutating the 
NF-κB site in the promoter region was performed by PCR using primers P23 and P24. 
The IL-8 promoter region was amplified by PCR on Huh7 genomic DNA using primers 
P25 and P26 and inserted into the KpnI/HindIII site of the PGL4 vector. The 3′- UTR 
region of the human (158 bp) and mouse (177 bp) EPO mRNA, containing two putative 
miR-122 target sites, were PCR amplified from human or mouse liver DNA using 
primers P27-P28-2 and P29-P30 respectively (see Supplementary Figure 9 and 
Supplementary Table 3). The PCR fragments were inserted into the pmirGLO vector 
(Promega) between the XhoI and SalI restriction sites, downstream of the firefly 
luciferase reporter gene. The 3′- UTR of human AldoA and the human DNMT1 mRNAs 
were PCR amplified using primers P31-P32 and P33-P34 respectively, and cloned in the 
pmirGLO vector between the SacI-XbaI sites. For construction of the miR-122 tester 
plasmid, primers P38-P39 were annealed and inserted between the SacI and XbaI sites of 
pmirGLO (see Supplementary Figure 3 and Supplementary Table 3).  
  
 
 
Supplementary Material and methods
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Luciferase Assay 
For Luciferase assays, cells grown in 24 well plates were co-transfected with a luciferase 
reporter plasmid (50 ng) and 1 ng of Renilla Luciferase vector (PRL, Promega) using the 
TransIT-LT1 (Mirus) transfection reagent (MIR 2300, Madison, WI). In experiments 
where Luciferase reporter plasmids were transfected together with mimic-microRNA or 
antago-miRs, (50 nM) cell transfection was performed with Lipofectamine LTX 
(Invitrogen). Firefly and Renilla luciferase activity was assessed using the Dual 
Luciferase Reporter Assay system (Promega). Readings were taken in triplicates on a 
Mithras LB 940 Luminometer (Berthold Technologies).  
 
Cell Proliferation Assay 
Cell proliferation assay was performed with the CellTiter 96 Aqueous One Solution cell 
proliferation assay (MTS) (Promega) on Huh7 cells seeded in 96-well plates and 24 hours 
later, cells were treated with TNF (5ng/ml) for 24 hrs. Antitumour antibiotic 
Doxorubicin (DOX) 2µg/ml was used as a proliferation inhibitor control. After 24 hours, 
MTS solution was added (20 μl/well), and cells were incubated for 3 hours at 37°C. The 
number of living cells in the culture was determined by absorbance at 490 nm with a 96-
well plate reader. The data is presented as the mean ± SD (n=3).  
 
In Vivo Luciferase Activity Monitoring by the IVIS Camera 
For in vivo bioluminescence imaging, mice were hydrodynamic tail vein injected with 
2 ml saline containing 5 μg of the human PmiR-122-900 luciferase reporter plasmid. One 
day after injection, the animals were injected i.p. with 500 μl of D-luciferin (Promega). 
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Ten minutes after luciferin injection, mice were imaged using an IVIS-200 CCD camera 
(IVIS-200; Xenogen, Alameda, CA). Immediately after imaging, mice were i.p. injected 
with LPS (1mg/kg mice) or with saline and imaged again 3 hours later and at days 1, 2, 5, 
6 and 7 after LPS injection. Luciferase quantification was done using Living Image® 
software (Xenogen Corp.). In vivo luciferase activity is expressed as photons/second/cm2. 
 
Induction of Anemia with Phenylhydrazin 
Anemia was induced with Phenylhydrazin (PHZ) (30 mg/kg body weight) (Sigma 
Chemical, St Louis, MO) by i.p. injection on 2 consecutive days in 200 ul saline. In the 
experiment with mimic-miR-122, four days after the second PHZ injection, mimic-miR-
122, miR-control (siScrambled) or siEPO were i.v. injected (0.1 mg/mouse in 200ul 
saline) and 2 days later, blood was taken for measurement of EPO protein levels. In the 
experiment with repression of miR-122, mice were i.v. injected with antago-miR-122 or 
antago-miR-124 (negative control) (5 ug/mouse in 1.5ml saline) and the next day, blood 
was drawn for measurement of reticulocytes, hemoglobin and EPO levels. Mice were 
then i.p. injected with PHZ on 2 consecutive days and blood was taken at 7 and 12 days 
after the second PHZ injection for measurements of reticulocytes, hemoglobin and EPO 
levels.  
 
Induction of Acute Pancreatitis by Cerulein 
C57BL/6 mice, 7-8 weeks old, were injected intra-peritoneally (i.p.) with 50 μg/kg 
Cerulein (C9026, Sigma-Aldrich) in 0.1 ml of saline, repeatedly every 1 h (a total of 6 
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injections). Saline was injected as control. Mice were sacrificed 1 hour after the last 
cerulein treatment. 
 
Macrophage Depletion by Clodronate 
C57Bl/6 mice (7-8 weeks old) were injected i.p. with 200 μl of clodronate liposomes or 
with phosphate-buffered saline (PBS) liposomes (purchased from 
clodronateliposomes.org), two days before LPS injection (1mg/kg). The rat antimouse 
F4/80 antigen (No. MCA497) was purchased from; AbD Serotec (ENCO ). 
 
A Mouse NASH Model 
The mouse CD-HFD model, recapitulating key features of the human metabolic 
syndrome – Non-Alcoholic SteatoHepatitis (NASH), was induced by long-term feeding 
with a Choline-Deficient High-Fat Diet, developed by Heikenwalder et al.{Wolf, 2014 
#81}. At the age of 12 months, these mice have a significant elevated TNF serum 
levels. Blood was sampled at 12 months of age of these mice and measured for EPO 
protein and miR-122 levels.  
 
 
RNA Extraction and Quantitative Real-Time PCR Analysis 
Total RNA, including small RNAs, were isolated from 200 μl of plasma or culture media 
samples using the miRNeasy Mini kit (Qiagen, Valencia, CA,USA) with 2 minor 
modifications. First, 200 μl of plasma or culture media were lysed with 1ml of Qiazol 
solution. Second, a 50 pmol/l of synthesized single strand Caenorhabditis elegans 
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miRNA (cel-miR-39) was added as the spike-in control to monitor extraction efficiency. 
The remainder of the RNA extraction was performed according to the manufacturer's 
instructions. miRNAs were eluted with 30 μl of RNase-free water. 
Total RNA, including miRNAs, from cells or tissues were isolated using TRIzol reagent 
(Invitrogen, Carlsbad, CA, USA). cDNA was synthesized using the Quanta Biosciences 
qScript ™ cDNA Synthesis Kit (95047-100) for mRNA analysis, and using the qScript™ 
microRNA cDNA Synthesis Kit (95107-100) for miRNAs analysis . qRT-PCR of 
miRNAs and mRNA was performed using the ABI 7900 HT Real-Time PCR System and 
a SYBR Green PCR Kit: Quanta Cat. #84018 and #84071 respectively. The fold 
expression and statistical significance were calculated using the 2 -∆∆ Ct method. All 
experiments were performed in triplicates. The primers used for qPCR are shown in 
Supplementary Table 2. 
 
Synthetic small RNA  
Small RNA duplexes were purchased from Syntezza Bioscience Ltd (Israel). The 
microRNA inhibitors: Antago-miR-122 and antago-miR-124, were purchased from 
Sigma Aldrich (Israel).  
Mimic-miR-122:  sense:5'-CAAACACCAUUGUCACACUCCATT-3' 
antisense: 3'- TTGUUUGUGGUAACAGUGUGAGGU-5' 
Modified  miR-122:  sense:5'-mCmAAACACCAUUGUmCACACUCmCmAdTdT-3' 
antisense: 5'-mUmGGAGUGUGACAAUGGUGUUmUGdTdT-3' 
siEPO (modified) :  sense: 5'-mGACCCUmUCAGCUUCAUAmUmAdTdT-
3'antisense: 5'–mUAUAUGAAGCUGAAGGmGmUCdTdT-3' 
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si-Scrambled :sense: 5'-GmUmUGGAGmGCGGUAmUGUGmAGdTdT-3' 
antisense: 5'–CmUmCACAUACCGCCUCCmAmACdTdT-3' 
 
Northern Blot Analysis 
Total RNA (40 μg) from human liver or Huh7 cells was separated on a 1.2% 
formaldehyde agarose gel and transferred onto GeneScreen Plus® Hybridization Transfer 
Membrane. For RNA size determination we used the RNA Millenium Size Markers-
Formamide (Ambion, Cat. # 7151). Radioactive α-32P-dCTP labelling of the probes was 
carried out using Random Primer DNA Labeling Mix (Biological Industries, Beth 
Haemek, Israel). Membranes were hybridized with ExpressHyb-Hybridization Solution 
(Clontech). 
 
mRNA 3’ RACE Analysis 
RNA was extracted from Huh7 cells using the TRIzol reagent (Invitrogen) and subjected 
to 3’-RACE analysis using the GeneRacer kit (Invitrogen). cDNA was generated with 
primer P5 followed by a first PCR amplification using the pri-miR-122 specific forward 
primer P11, and the GeneRacer 3' primer (P10). A second PCR was performed on the 
first PCR reaction using nested pri-miR-122 primer, P13, and the GeneRacer 3' Nested 
Primer, P12 (Figure 1). The amplified 3'RACE fragment from the second PCR, was 
purified and sent for sequence analysis (Supplementary Figure1). See Supplementary 
Table 1 for primer sequences.  
Human Blood Samples  
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For analysis of blood samples collected from patients with inflammation, we submitted 
and received an IRB approvals for the collection of blood samples for the measurement 
of miR-122 and EPO both from the Hamburg-Eppendorf University Hospital and 
Hadassah Hebrew University Hospital. The samples received from Hamburg-Eppendorf 
University Hospital were obtained from the “Liver.net” biobank, which was established 
by the Collaborative Research Centre 841 at Hamburg University Medical Center.  
 
Hematological Blood Parameters  
Blood from the retro-orbital plexus was collected into microcapillaries. The hemoglobin 
content was analyzed by Reflotron Hemoglobin test (REF 10744964, Roche diagnostic). 
Reticulocyte numbers were measured using the COULTER® LH780 Hematology 
Analyzer (Beckman Coulter, Inc., CA, USA) and EPO plasma levels were determined by 
mouse EPO Quantikine ELISA kit (MEP00B, R&D Systems). 
 
Immunofluorescence staining  
Liver tissue was cut into 5 mm sections, deparaffinized with xylene and hydrated through 
graded ethanol. For GFP (ab6673, Abcam) staining, a 25mM citrate buffer pH 6.0 was 
used for antigen retrieval, cooked in a pressure cooker for 20 min and left to cool for 30 
min at room temperature. Slides were washed in Optimax (Pharmatrade) and incubated 
with primary antibody (diluted in CAS-Block (Zymed) 1:250, over night at 40C. Sections 
were rinsed in PBS and incubated with 488-conjugated donkey anti- gout 
immunoglobulin G (Jackson ImmunoResearch Laborato- ries). Sections were washed 
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twice in PBS for 5 min, in ddH2O twice for 5 min, and were mounted with fluorescent 
mounting media. 
 
Chromatin Immunoprecipitation (ChIP) 
ChIP assay was performed as described in Rubins et al., (2005) Molecular and Cell 
Biology, Vol. 25:7069-77, and in Jun Yang et al., (2015) Mol Cell Proteomics, 
Vol.14(10):2701-21. Briefly, Huh7 cells (1x107) were treated with TNF (5ng/ml) for 2 
or 16 hrs. Cells were then fixed with 1% formaldehyde, lysed and the chromatin was 
sheared by sonication for 15 minutes. The chromatin was then immunoprecipitated using 
the Anti-p65 Antibody (ab7970 abcam). Real-time PCR was performed to quantify the 
relative enrichment of immunoprecipitated DNA. The relevant primers are listed in 
Supplementary Table 2. The enrichment of target genes was calculated using the GAPDH 
as a reference for nonspecific DNA, and is shown relative to the input Chromatin. 
 
Statistical Analyses  
All data were subjected to statistical analysis using the 
Excel software package (Microsoft) or GraphPad Prism6 (GraphPad Software Inc., La 
Jolla, CA, USA). Two-tailed Student’s t- tests and Pearson's correlation coefficients were 
used to determine the difference between the groups. Data are given as mean ± SD, and 
are shown as error bars for all experiments. Differences were considered significant at P 
< 0.05. To determine group sizes necessary for adequate statistical power, power analysis 
was performed using preliminary data sets. The exclusion criterion was set to be 1.5 s.d. 
from the mean. No data met this criterion, and thus all data points were included in the 
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analysis. The investigators were blinded to group allocation during collection and 
analysis of the data. 
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9.0
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2.0
1.0
4.0
Probe:  Intron2 + Exon3 Intron1
Huh7Huh7LiverM (kb)
Exons:
Exon
Junction
1‐2  2‐3 2‐3    1‐3  
Spliced
Pri‐miR
1000‐
500‐
200‐
Primers:   P9+P8   P7+P6   P7+P1  P9+P1
PCR
1st 2ndM
1000‐
3'‐RACE
500‐
200‐
Human pri‐miR‐122
USCS 2013/hg38 
chr18: 58446264 – 58451276  2970 bp 1440 bp
+1 miR‐122
AAAAAGUGU AG AG Exon3
295 bp
Exon1
76 bp
Exon2
231 bp
1st PCR
2nd PCRP13 P12
P10 P11
3’ RACE
P6P7
P8P9Exon Junction: Exons 1‐2Exons 2‐3
P1P2P3P4Hybridization probes
P5 cDNA
Spliced pri‐miR: P1P9
P7Exons 2‐3
Exons 1‐3
Supplementary Figure 1. miR-122 is generated from the third exon of a 5 kb pri-miR-122 transcript carrying three exons. (A) A 
schematic presentation of pri-miR-122 with the sizes of the 3 exons and the introns and its coordinates in the USCS 2013/hg38 
assembly, and the primers used for the analysis (see primer sequences in Supplementary Table 1). (B) cDNA generated by RT-PCR on 
Huh7 RNA using primer 5, followed by PCR to identify the spliced RNA structure. (C) PCR reactions to identify the pri-miR-122 3’-end 
using a 3’-RACE kit (invitrogen). All PCR products were sequenced (see Supplementary Figure 2). (D) Northern blots were probed with 
PCR fragments carrying the Intron2-Exon3 region or a region of intron1, generated by the indicated primers (1+2 and 3+4 respectively, 
Table S1). This analysis yielded two prominent bands, one 5.0 kb (corresponding to full pri-miR-122), and 2.0 kb. The small Pre- and 
mature miR-122 RNA  run-off these gels. The 2.0 kb fragment yielded a signal with mature miR-122, but not with a probe carrying only 
intron1 sequences, indicating that it is a partially spliced product lacking intron1.
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..AGCAGAGCTGTGGAGTGTGACAATGGTGTTTGTGTCTAAACTATCAAACGCCATTATCACA
CTAAATAGCTACTGCTAGGCAATCCTTCCCTCGATAAATGTCTTGGCATCGTTTGCTTTGAGC
AAGAAGGTTCATCTGATATCAGTCTTCTCAATCTTGTGTACTTACTGAATAAAGTCTGGCTCT
TTTGCACTCATAAAAAAAAAAAAAAAAAA...
Pri‐miR‐122  3’‐end
(58451276  USCS 2013/hg38)
miR‐122
PolyA signal
Sequence of  3’‐ RACE  (Figure S1B)
Primer P13 ‐ 2nd PCR
..TGCCTTGGACTGAGAGGACCGGAGCTGACTGGGGATTATTCAAAGCCAAAAGCCAA
CAGAGCCCCCATGGAGAAGTGGAGGATGCTCAGATACTGCTATGGAGCCCTGAGAAGT
GAAATGGGTCCAAGCCCTTGCCCAGGATAGAGCGCTCCAAGCGCATCctCCGGGGACC
CTTTTAATCAGTGAGAT...
Exon1 Exon2
Sequence of  Exon 1‐2 junction (Figure S1C)
..TCATGGAGAAGTGGAGGATGCTCAGATACTGCTATGGAGCCCTGAGAAGTGAAATGGGTCC
AAGCCCTTGCCCAGGATAGAGCGCTCCAAGCGCATCCTCCGGGGACCCTTTTAATCAGTGAAT
TGTTCACCTCTCACTGTTTCTTCCCAGCAGAGCTAAGAGACTTCTAGAGCCTCTTGTGGATGG
TCAGCGATAGCCCTGGTCACAATATGTGGAGCTGACAAGGTTCCCCTATTATCAGTGACAATG
GTGGAATGTGGAGGTGAAGTTAACACCTTCGtGGCTACAGAGTTTCCTTAGCAGAGCTGTGGA
GTGtGACAATGGTGTTTGTgTCTAAACTaTCAAACGCCaNT...
Exon2
Exon3
Sequence of  Exon 2‐3 junction (Figure S1C)
A
B
C
Supplementary Figure 2. Determination of the pri-miR-122 structure and its 3’-end. Sequencing results of 
products of RT-PCR reactions performed on cDNA obtained with primer P5 (Supplementary Figure  1). (A) 
Sequencing of 2nd PCR product of the 3'-RACE analysis generated with primers P13 and P12. The terminal 
nucleotide at position 58451276 is annotated. Mature miR-122 sequence is shown in blue, the position of primer 
P13 is shown in yellow and the polyA signal sequence is shown in gray.  (B) DNA sequencing of the PCR 
product generated with primers P9 and P8 (Exon 1-2 junction). (C) Sequencing of PCR product generated with 
primers P7 and P6 (Exon 2-3 junction). The DNA sequence of Exon2 is shown in red. 
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Supplementary Figure 3. DNA sequence of the miR-122 promoter region. (A) The miR-122 promoter region, 
extending to -900 or to -250 bp from the transcription start site (TSS) was amplified by PCR on human liver DNA,  
using primers P20 and P21 or P22 and P21 respectively (yellow). PCR products were digested with HindIII (light 
blue) and MluI (added to the 5’-end of primers P20 and P22, see supplementary Table 3), and cloned into the PGL4 
vector, yielding plasmids PmiR-122-900 and PmiR-122-250 respectively.  The NF-kB site at position -170 from TSS 
is marked in green. The cloned promoter region extends to +270 bp and includes Exon 1 (marked in grey). (B) 
Primers used for construction of the miR-122 tester plasmid in pmirGLO. 
A P20 (-900)                                 
…GAGGATCACCTGAGGTCAGGAGTTTGGGACCAGCCTAGTCAACATGGTGAAACCCCGTCTCTACTAAAAATACAAAAATTAG
CCGGGCGTGGTGGCGGGCACCTGTAGTCCCAGCTACCCAGGAGGCTGAGGCAGGAGAATCGCTTGAATCCGGGAGGCGGAGGT
TGCAGTGAGCCAAGATCACGCCACTGCACTCCAGCCCGGGCAACTGAGCGAGACTCCATTTCAAAAAAATAAGTAAATAAAAA
ATAAAAAGCAATAATAATAGCCGACAACAGAATACAGCTAGGCCGAGCAGCAGCCTCCTCTGCTGTCCGTGCGGCTCGCCTGT
TGCCTGCTTCACTGCCTGACTGTGGGCTCTGTTTGTCTTGGTCCCCGTGGCATTACCAGAGCTTAGCAGATAAGGAGGAGCTT
CATACATAATTGTTGGCGTGAACAAAGGAATGCATGGTTAACTACGTCAGAAATGACCAGTTCAAGAGGAGAATGAGATTGGC
TTCCAAATGTTGGTCAAGAGCTCTACGTAGCATGAGCCAAGGATCTATTGAACTTAGTAGGCTCCTGTGACCGGTGACTCTTC
TGTCTCTAGAAATCTGGGGAGGTGACCAGGTCATACATGGCAGTCTTCCCGTGAGGAACGTTAAACTGGTTGGAAGTTGGGGT
P22 (-250)                                        
TCTGAGGGGAAGATGTATTCACTAGGTGACCTGTCTTCTCTGCCTCGGTGGCCTCCATGGCTGCCTGCTGGCCGCACACCCCC                      
NF-kB                                                              
ACTCAGCAGAGGAATGGACTTTCCAATCTTGCTGAGTGTGTTTGACCAAAGGTGGTGCTGACTTAGTGGCCTAAGGTCGTGCC
CTCCCTCCCCCACTGAATCGATAAATAATGCGACTTATCAGAAAGAGAAAGAATTGTTTACTTTTAAACCCTGGATCCCATAA
TSS                           Exon1                   
AGGGAGAGGGGAGAGGCCTAAAGCCACAGAAGCTGTGGAAGGCGCCATCCTGCCTGCCACAGGAAGGGCCTTGGACTGAGAGG
ACCGGAGCTGACTGGGGGTAAGTGCGGCTCTCCCCCGGCGCCTGCCGACCCCCCTGAGTGATCAGGCCGTTCTTTGGGGTGGC
CGCTGACCGAGAAATGACGGGAGGCTGCTGACTCCGGTGTTGAAAAAGATGCCACCCAGCGCCTGAGCAACAGGAGGTGTTGA
HindIII (+270)
ACACACCATAACTTTGTCTTCCATGATTATTCTGTTTCCTCAGAAAGCTTGAGGAAAACTGGAGACTTTCTTTAGAGAGAGTA
ACAGATGGTTTCCGTTTAAAGAAAAATAACAAAATGGCTTAAGGAGGAAAAGAAATGATCACCCTGCAGAGGGAGAGAGGATG
AGGCTGGGGAGGAGCTGAGGGCTCAGGGACGGTGTGGGGTTTTATTTCTGCCCTTGGAGTGGCTGGACATTAAGCCAGTTCTT
GTTTTTACGATGGCCTGATTCAGCAATAACACCAAACCTTCAAACAAAATGCCGGCATTAGAGTCGTTCCTTTGGCATGCCTC
TGTCCAGGTCATATTGTTCCCTCAATAGCACTAAAAATAGCTGGACACCTGTGCA..                 P21                            
SacI XbaI
5’- CCAAACACCATTGTCACACTCCAT -3’
3’- TCGAGGTTTGTGGTAACAGTGTGAGGTAGATC-5’
B
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Supplementary Figure 4. Analysis of miR-122 promoter activity. (A) Expression of the miR-122 promoter in 
different cell lines. Cells were grown in a 24 well plate and transfected with plasmid PmiR-122-900 (50 ng). (B) Serial 
shortening of the miR-122 promoter from the 5’-end performed by PCR on DNA of the PmiR-122-900 plasmid, using 
forward primers corresponding to the sequence at the indicated distance from TSS (carrying an MluI or KpnI site at 
their 5’-end, Supplementary Table 3) and a reverse primer from the vector. The PCR fragments were digested with 
MluI or KpnI and HindIII (located at the 3’-end of the original promoter fragment, +270 from TSS) and inserted into 
the PGL4 vector. The plasmids (50 ng) were then used to transfect Huh7 cells grown in 24 well plates. Luciferase 
(Luc) activity was measured 48 hours after transfection and normalized to Renilla Luciferase activity expressed from 
a co-transfected pRL plasmid. Error bars = SD. 
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Supplementary Figure 5. Mature miR-122 is generated solely from the long pri-miR-122 transcript driven 
by the upstream promoter.  Rational: Since the miR-122 promoter is expressed only in Huh7 cells, we 
exchanged the WT pre-miR-122 sequence within a plasmid carrying the entire miR-122 genomic region, with a 
mutated pre-miR-122, in order to distinguish its expression from the endogenous WT miR-122 of Huh7 cells.  
Experimental design:   (A) Huh7 cells (that express endogenous miR-122) were transduced with plasmids 
harboring the mutated miR-122 genomic region, cloned with (full) or without (Δ) the promoter region. (B) 48 hours 
after transfection, RNA was extracted for qRT-PCR analysis of the mutant miR-122 (using a specific miR-122 
mutant primer) which was normalized to RNU-43.  Results: Deletion of the upstream promoter region abolished 
miR-122 expression, indicating that it is the only driver of the miR-122 transcript. 
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Supplementary Figure 6. Activation of the miR-122 promoter by TNFα is specific and is NF-
κB-dependent. (A) Huh7 cells were co-transfected with 50 ng of PmiR-122-250 or the NF-κB 
reporter plasmid, together with a plasmid expressing the IKB∆N inhibitor (50 ng), a dominant-
negative NF-kB inhibitor which remains attached to NF-kB and does not release it to enable NF-
kB activity. (B) Cells transfected with reporter plasmids for PmiR-122-250 and the human AAT and 
EF1α promoters (which served as negative controls) and 24 hours later, treated with TNFα (5 
ng/ml) for 24 hours.  Luciferase (Luc) activity was measured 48 hours after transfection and 
normalized to Renilla Luciferase activity expressed from a co-transfected pRL plasmid. Error bars = 
SD. *P< 0.05; **P< 0.01.
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Supplementary Figure 7. TNFα enhances both, pri‐miR‐122 and mature miR‐122 levels in Huh7 
cells. qRT‐PCR analysis of pri‐miR‐122 (A) and mature miR‐122 (B) in RNA extracted from Huh7 cells 
treated with TNFα for 24 hours. Mature miR-122 was normalized to RNU-6, pri-miR-122 levels 
were normalized to HPRT. Error bars = SD. *P< 0.05; **P< 0.01.
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Supplementary figure 8. C/EBPα represses the wt and the mutant miR-122 promoter. Relative 
Luciferase activity in Huh7 cells, plated in a 24 well plate, co-transfected with 50 ng of wild type (wt) or 
mutant (mut) PmiR-122-250 plasmids or with an IL-8 reporter plasmids as a positive control (known to be 
activated by both, C/EBPα and NF-kB), together with a plasmid expressing P65 (25 ng), or the human 
C/EBPα (50 ng). Luciferase activity was measured 48 hours post transfection and normalized to Renilla
Luciferase activity expressed from a co-transfected pRL plasmid. Error bars = SD. *P< 0.05; **P< 0.01
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Mouse EPO 3’‐UTR (Two putative miR‐122 sites)
site1
GTGACATGCTGCTGCCACCGTGGTGGACCGACGAACTTGCTCCCCGTCACTGTGTCATGCCAACCCTCCACCACTCCCA
ACCCTCATCAAACGGGTCATTACCTTCTTACCAGTCTGTCCCATGGACACTCCAGCACCAGCAGTGACATCCTCGGGGC
CAGAAGAACTTCCCAGAGCTCC..     .................. site2
P29
P30
A
GT ATC CA T  TATG
||  |||    ||       |  ||||
..TCAGCTCAGCGCCAGCCTGTCCCATGGACACTCCAGTGCCA...
Mutatating the conserved miR‐122 site (site2) in the human EPO 3’‐UTRD
Supplementary Figure 9. Putative miR-122 target sites in the 3'-UTR of erythropoietin (EPO). (A and B)
The sequence of the mouse and human EPO 3'-UTR region containing the putative miR-122 target sites. The 
miR-122 seed target and additional potential miR-122 binding sites are shown in red. The TGA translational 
stop codon of EPO is shown in green. The position of primers used for cloning the 3’-UTR into the pmirGLO
plasmid are shown with an arrow. Complete primer sequences are shown in Supplementary Table 3. (C) Site2 
is highly conserved between mouse and human EPO. (D) Mutations (shown in blue) that were introduced into 
the putative miR-122 site2 in the human EPO 3’-UTR. 
Human EPO 3’‐UTR (Three putative miR‐122 sites)
TGACCAGGTGTGTCCACCTGGGCATATCCACCACCTCCCTCACCAACATTGCTTGTGCCACACCCTCCCCCGCCACTCC
TGAACCCCGTCGAGGGGCTCTCAGCTCAGCGCCAGCCTGTCCCATGGACACTCCAGTGCCAGCAATGACATCTCAGGGG
CCAGAGGAACTGTCCAGAGAGCAACTCTGAGATCTAAGGATGTCACAGGGCCAACTTGAGGGCCCAGAGCAGGAAGCAT
TCAGAGAGCAGCTTTAAACTCAGGGACAGAGCCATGCTGGGAAGACGCCTGAGCTCACTCGGCACCCTGCAAAATTTGA
TGCCAGGACACGCTTTGGAGGCGATTTACCTGTTTTCGCACCTACCATCAGGGACAGGATGACCTGGATAACTTAGGTG
GCAAGCTGTGACTTCTCCAGGTCTCACGGGCATGGGCACTCCCTTGGTGGCAAGAGCCCCCTTGACACCGGGGTGGTGG
GAACCATGAAGACAGGATGGG..              site3
P27
P28‐3
P28‐2
B
...................... site2
site1
Mouse site2 CCAGTCTGTCCCATGGACACTCCA
Human site2 CCAGCCTGTCCCATGGACACTCCA
C
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Supplementary Figure 10. ( A) Blood microRNA  levels in PHZ treated mice. Mice were 
injected i.p. in two successive days with PHZ (30 mg/kg) and 4 days after the second PHZ 
injection, mice were injected i.v. with mimic miR-122,  miR-scrambled (miR-con), or siEPO
(0.1mg/mouse) (modified for stability, see Materials and Methods). (B) The effect of antago-
miR-122 on plasma miR-122 levels. C57BL/6 mice were injected i.v. with antagomiR-122 
(5μg/mouse) (Ant-122) or antagomiR-124 (Ant-124) and 24 hours later miR-122 plasma 
levels were determined. miR-18a served as a negative control.. MicroRNA plasma levels 
were measured two days after injection by qRT-PCR and normalized to spiked-in C.elegans
miR-39 ( Cel miR-39) (n=4).
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Supplementary Figure 11. The effect of LPS on mRNA levels of TNFα and miR-122 target 
genes in the kidney. C57BL/6 mice were injected i.p. with LPS (1mg/kg) and were sacrificed 5  
and 24 hours later and RNA extracted from the liver and kidneys for qRT-PCR analysis of TNFα
(A and B) and the miR-122 target genes AldoA and AGPAT1 (C). RPL4 served as a negative 
control. Kidney TNFα, AldoA, AGPAT1 and EPO mRNA levels were normalized to HPRT. Error 
bars = SD. *P< 0.05; **P<0.01; ***P<0.001.
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Supplementary Figure 12. Inhibition of miR-122 does not affect spleen size or weight in antagomiR-
122 and LPS-treated mice. Mice (C57Bl/6) were i.v. hydrodynamically injected with antagomiR-122 or 
antagomiR-Scr as control (5µg/mouse) 3 days before and one day after the first LPS injection (0.5 ug/gr). 
Two additional LPS injections were administered at days 2 and 4 (see experimental design in Figure 7C). 
Mice spleens were measured at day 7 after the first LPS injection for their length (A) and their weight (B). 
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Supplementary Figure 13. GFP Immunofluorescence staining of a paraffin embedded liver 
tissue. The miR‐122 promoter GFP reporter plasmid (10 ug) was administered into mice by 
hydrodynamic tail vein injection. One day later, LPS (1 mg/kg) was i.p. injected and the mice were 
sacrificed 24 hours later.  Liver sections were immuno‐stained with Anti‐GFP antibody. The figure 
demonstrates that plasmid GFP, driven by the miR‐122 promoter, is expressed in hepatocytes and 
is significantly induced by LPS.
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Supplementary Figure 14. Chromatin immunoprecipitation (ChIP) assay. Huh7 cells (1x107) were treated with 
TNF (5ng/ml) for 2 or for 16 hrs. Cells were fixed with 1% formaldehyde, lysed and the chromatin was sheared 
by sonication for 15 minutes. The chromatin was then immunoprecipitated using the anti‐p65 antibody 
(ab7970 abcam). Real‐time PCRs were performed to quantify the relative enrichment of immunoprecipitated
DNA using primers shown in Supplementary Table 2. The enrichment of each target gene was calculated using 
the GAPDH as a reference for nonspecific DNA, and taking into account the amount of input. Data are 
expressed as fold change relative to unstimulated cells.
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Supplementary Figure 15. Hepcidin mRNA levels determined by qRT‐
PCR performed on liver RNA of the various mouse models of 
inflammation. (A) Reduced hepcidin levels in CD‐HFD mice. RNA 
extracted from livers of 12 months old CD‐HFD C57BL/6 mice (HFD) 
(exhibiting features of human NASH  induced by long‐term feeding of a 
Choline‐Deficient High‐Fat Diet) or from mice fed a normal diet (Con) 
(n=5); (B) Increased hepcidin level in cerulein treated mice (6 hourly i.p. 
injections, 50µg/kg) liver  RNA extracted1 hour after last injection. See 
legend of Fig. 5)(n=4); (C) LPS model of inflammation‐induced anemia.
Mice were i.p. injected with LPS (0.5mg/kg) or Saline (Con) for four 
successive injections at days 0, 2, 4 and 7. Liver hepcidin levels were 
determined at 6 hours, 24 hours and at day 8 after the first LPS 
injection (n=6). (D) miR‐122 negatively regulates hepcidin. Analyses of  
liver mRNA levels of hepcidin and the hepcidin activators Hfe , Hjv and 
Bmpb1 in mice treated by antago‐miR‐122 and antago‐miR‐control 
followed by LPS injection. RNA extracted 5 hours after LPS injection 
(see experimental design in the legend of Fig. 7). 
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Supplementary Table 1. Primers used for characterization of pri-miR-122 
   
 
 
Primer 
number 
Sequence (5’→3’) Direction Purpose 
Product 
length 
(bp) 
P1 GTTATGAGTGCAAAAGAGCCAG Reverse Hybridization 
Probe                             
Intron2 + 
Exon3 
1260 
P2 
TGCAAGTCCAGCTTGAAGAGGG Forward 
P3 TTTACCTATAAGGTTGCTCATAGTGGC Reverse Hybridization 
Probe           
Intron1 
466 
P4 GATGGGTTCCAACCTTCCC Forward 
P5 GCTGTCAACGATACGCTACGTAACGGCATGACAGTG(T)24  Reverse 
cDNA 
(Invitrogen 
3'-RACE) 
  
P6 AAGGATTGCCTAGCAGTAGC Reverse 
PCR Exon2-3 384 
P7 CATGGAGAAGTGGAGGATGC Forward 
P8 GGAAGAAACAGTGAGAGGTG Reverse 
PCR Exon1-2 210 
P9 GCCTTGGACTGAGAGGACCG Forward 
P10 GCTGTCAACGATACGCTACGTAACG Reverse 3'-RACE 1st 
PCR   P11 CTGGTGTTTGTGTCTAAACTATCAAACGCC Forward 
P12 CGCTACGTAACGGCATGACAGTG Reverse 3'-RACE 2nd 
PCR 
180 
P13 AATACGTACTGCTAGGCAATCC Forward 
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Table S2. Primers for real-time PCR
Gene Direction Sequence (5’→3’)
forward GGACAGGACTGAACGTCTTGC
reverse CAACACTTCGTGGGGTCCTT
forward GTCCCAGACACCAAAGTTAATTTC
reverse  GCCCTGCCAGACTTCTAC
forward GCCTTGGACTGAGAGGACCG
reverse GGAAGAAACAGTGAGAGGTG
forward GCGATGATGAACCAGGTTATGA
reverse ATCTCGAGCAAGTCTTTCAGTCCT
forward CTTCACTGCTTCGGGTACTGG
reverse GTGTACAGCTTCAGTTTCCCC
forward CCATCAAACGCCATTATCACACTA
reverse  CACACAATGGAGAACTCTAGCACAA
forward CTGTAGCCCACGTCGTAGCAA
reverse CTGGCACCACTAGTTGGTTGTTC
miR-122 forward TGGAGTGTGACAATGGTGTTTG
miR-18a forward TAAGGTGCATCTAGTGCAGATAG
miR-16 forward TAGCAGCACGTAAATATTGGCG
RNU-44 forward
CCUGGAUGAUGAUAAGCAAAUGCUGACUGAACAUGAAG
GUCUUAAUUAGCUCUAACUGACU
RNU-6 forward
GUGCUCGCUUCGGCAGCACAUAUACUAAAAUUGGAAC
GAUACAGAGAAGAUUAGCAUGGCCCCUGCGCAAGGAU
GACACGCAAAUUCGUGAAGCGUUCCAUAUUUU
Cel-miR-39-3P forward TCACCGGGTGTAAATCAGCTTG
forward CACCGTCTGTGCCATCTTCTT
reverse ACATAGCCACCCATGGTTCCT
forward CAGCTCCCCGGTTTCGT
reverse TGGTAGACTTTCTGGTCAATGCA
forward CAGTTTTATCTAGCCACATCTCTGA
reverse GGGAGGCTTCCTTACAGAACA
forward  CTGAGCAGCACCACCTATCTC
reverse TGGCTCTAGGCTATGTTTTGC
Primers for CHIP assay
forward TCTGCTGTAGGCTCATTTGCAG
reverse TCACCTGATGATCTTGAGGCTG
forward AGAAAACTTTCGTCATACTCCG
reverse AGAGGAAATTCCACGATTTGC
forward GGAGTTTCTCCGATGAAC
reverse TCAGGCTCGGGGAATTTCC
forward TGCCTGCTGGCCGCACACCC
reverse CAAACACACTCAGCAAGATTGG
IL-8
IkBα
human miR-122 promoter
mouse Hfe
mouse Hjv
mouse Bmpr1a
Mouse Hepcidin
human GAPDH
Mouse TNFα
Human HPRT
Human EPO
Human pri-miR-122
Mouse HPRT
Mouse EPO
Mouse pre-miR-122
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Supplementary Table 3. Primer for plasmids constructs 
 
     
Primer 
number 
Direction Sequence (5’→3’)ab 
Restriction 
Sites at 5'-
end  
Cloning 
 P20 forward GACACGCGTAGTCAACATGGTGAAACCC MluI miR-122 
promoter (-900)   P21 reverse GACCTGGACAGAGGCATGCCAAAGG   
 P22 forward CTCTTACGCGTGACCTGTCTTCTCTGCCTCGG MluI 
miR-122 
promoter (-250) 
 P23 forward AATGGACTCTCGAGTCTTGCTGAGTGTG 
  
mutate NF-kB 
site in mir-122 
promoter  P24 reverse CAAGACTCGAGAGTCCATTCCTCTGCTGAG 
 P25 forward ATATTTGGTACCCTGCCACTCTAGTAC KpnI human IL-8 
promoter  P26 reverse ATATTTAAGCTTGTGTGCTCTGCTGTCTC HIndIII 
 P27 forward GCTAGCCTCGAGTGACCAGGTGTGTCCACC NheI XhoI 
human EPO 3'-
UTR 
 P28-2 
reverse                 
(2 miR-
122 sites) 
AACCTGCAGGTCGACCCTGAGATGTCATTGCTG PstI SalI  
 P28-3 
reverse                 
(3 miR-
122 sites) 
AACCTGCAGGTCGACCCTGTCTTCATGGTTCCCAC PstI SalI 
 P29 forward GCTAGCCTCGAGGTGACATGCTGCTGCCACC NheI XhoI mouse EPO 3'-
UTR  P30 reverse AACCTGCAGGTCGACAGCTCTGGGAAGTTCTTCTG PstI SalI 
 P31 forward  TAACCAGAGCTCCTCTTCGTCTCTAACCACG SacI human ALDOA1    
3'-UTR  P32 reverse  ACCAATCTAGAGCTGTTTATTTGGCAG  XbaI 
 P33 forward CCTCTGAGCTCCCAAAGCCCGAGAGAGTG SacI human DNMT1      
3'-UTR  P34 reverse ATGACTCTAGAAGAATGCACAAAGTACTGC XbaI 
 P35 forward TTAACCGGTACCTCAGCAGAGGAATGGAC KpnI 
miR-122 
promoter (-190) 
 P36 forward TTAACCGGTACCGTGTTTGACCAAAGGTGG KpnI 
miR-122 
promoter (-150) 
 P37 forward TTA CCGGTACCCCTAAGGTCGTGCCCTCC KpnI 
miR-122 
promoter (-120) 
     
a Bases written in italic were added to the primer 5'-end to add a restriction site. 
 
b Bases shown in red were substituted in order to mutate the NF-kB site in the miR-122 promoter  
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Supplementary Table 4. Changes in EPO and miR-122 levels in human  
patients during acute inflammation conditions 
  
       
Disease 
Number 
of 
patients 
Age 
miR-122    
EPO  
miR-122 
  EPO  
No 
change 
miR-
122/EPO  
miR-122   
EPO  
Acute Cholecystitis 10 18-71 7 2 1   
Pancreatitis 1 71 1       
Periappendicular 
abscess 
1 26 1       
Pneumonia 2 52, 82 2       
Urinary tract 
infection  
1 91 1       
Cholangitis 1 53   1     
Diverticulitis 1 68       1 
       ↑ Upregulated 
      ↓ Down regulated 
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Supplementary Table 3. Primer for plasmids constructs  
     
Primer 
number 
Direction Sequence (5’→3’)ab 
Restriction 
Sites at 5'-
end  
Cloning 
 P20 forward GACACGCGTAGTCAACATGGTGAAACCC MluI miR-122 
promoter (-900)   P21 reverse GACCTGGACAGAGGCATGCCAAAGG   
 P22 forward CTCTTACGCGTGACCTGTCTTCTCTGCCTCGG MluI 
miR-122 
promoter (-250) 
 P23 forward AATGGACTCTCGAGTCTTGCTGAGTGTG 
  
mutate NF-kB 
site in mir-122 
promoter  P24 reverse CAAGACTCGAGAGTCCATTCCTCTGCTGAG 
 P25 forward ATATTTGGTACCCTGCCACTCTAGTAC KpnI human IL-8 
promoter  P26 reverse ATATTTAAGCTTGTGTGCTCTGCTGTCTC HIndIII 
 P27 forward GCTAGCCTCGAGTGACCAGGTGTGTCCACC NheI XhoI 
human EPO 3'-
UTR 
 P28-2 
reverse                 
(2 miR-
122 sites) 
AACCTGCAGGTCGACCCTGAGATGTCATTGCTG PstI SalI  
 P28-3 
reverse                 
(3 miR-
122 sites) 
AACCTGCAGGTCGACCCTGTCTTCATGGTTCCCAC PstI SalI 
 P29 forward GCTAGCCTCGAGGTGACATGCTGCTGCCACC NheI XhoI mouse EPO 3'-
UTR  P30 reverse AACCTGCAGGTCGACAGCTCTGGGAAGTTCTTCTG PstI SalI 
 P31 forward  TAACCAGAGCTCCTCTTCGTCTCTAACCACG SacI human ALDOA1    
3'-UTR  P32 reverse  ACCAATCTAGAGCTGTTTATTTGGCAG  XbaI 
 P33 forward CCTCTGAGCTCCCAAAGCCCGAGAGAGTG SacI human DNMT1      
3'-UTR  P34 reverse ATGACTCTAGAAGAATGCACAAAGTACTGC XbaI 
 P35 forward TTAACCGGTACCTCAGCAGAGGAATGGAC KpnI 
miR-122 
promoter (-190) 
 P36 forward TTAACCGGTACCGTGTTTGACCAAAGGTGG KpnI 
miR-122 
promoter (-150) 
 P37 forward TTA CCGGTACCCCTAAGGTCGTGCCCTCC KpnI 
miR-122 
promoter (-120) 
     
a Bases written in italic were added to the primer 5'-end to add a restriction site.  
b Bases shown in red were substituted in order to mutate the NF-kB site in the miR-122 promoter  
 
